Bildkälla: Stockfoto

Xbrane Biopharma: Ximluci – CRL - Redeye

Redeye provides its initial comments on yesterday evening’s news that Xbrane has received a CRL from the FDA related to its Ximluci BLA. This means the FDA requires additional clarifications and a potential US approval will be delayed.

Redeye provides its initial comments on yesterday evening’s news that Xbrane has received a CRL from the FDA related to its Ximluci BLA. This means the FDA requires additional clarifications and a potential US approval will be delayed.
Börsvärldens nyhetsbrev
ANNONSER